GNCAQGENOCEA BIOSCIENCESGNCAQ info
$0.00info0.00%24h
Global rank
Market cap$5.88K
Change 7d0.00%
YTD Performance0.00%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Category
Business data

    GENOCEA BIOSCIENCES (GNCAQ) Stock Overview

    Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.

    GNCAQ Stock Information

    Symbol
    GNCAQ
    Address
    100 Acorn Park DriveCambridge, MA 02140United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.genocea.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    617 876 8191

    GENOCEA BIOSCIENCES (GNCAQ) Price Chart

    -
    Value:-

    GENOCEA BIOSCIENCES Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.0001
    N/A
    Market Cap
    $5.88K
    N/A
    Shares Outstanding
    58.78M
    N/A
    Employees
    74.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org